IDgenetix-Guided Medication Management for Major Depressive Disorder: Confirmation of Randomized Controlled Trial Outcomes by Real-World Evidence
This study compared the clinical outcome results from Bradley et al. (2018) with real-world evidence. Patient response and remission rates strongly aligned between both studies.
Publication: Poster at NEI Congress 2023
The Importance of Incorporating Drug-Drug Interactions and Lifestyle Factors in Pharmacogenomics-Guided Medication Management for Patients With Major Depressive Disorder in a Randomized Controlled Trial.
In this study, drug-drug interactions accounted for 32% of all IDgenetix-guided drug recommendations, and lifestyle factors accounted for 11%. Incorporating these non-genetic factors in IDgenetix testing significantly impacts the number of drug recommendations and improves remission rates in patients with moderate to severe depression.
Publication: Poster at Psych Congress 2023
Improved response and remission rates in patients receiving IDgenetix-guided medication management for major depressive disorder
In the study, patients whose medication management was guided by IDgenetix achieved a 35% increase in medication response and a 64% increase in remission compared to patients whose medication was not guided by the test
Publication: Poster at 2023 American Psychiatric Association (APA) Annual Meeting
Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: A rapid review and meta-analysis
Pharmacogenomic (PGx) testing may increase the probability of remission and response in patients with major depressive disorder (MDD) undergoing pharmacotherapy.
Publication: Psychiatry Res
Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomized controlled trials
Major depressive disorders are prevalent conditions with limited treatment response and remission. Pharmacogenomics tests including CYP2D6 and CYP2C19 genomic variants provide the most reliable actionable approach to guide choice and dosing of antidepressants in major depression to improve outcomes.
Publication: Neuroscience & Behavioral Reviews
Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta-Analysis of Prospective, Controlled Clinical Trials
IDgenetix-guided therapy demonstrated the most significant efficacy improvement of all. IDgenetix was 2.65 times more likely to achieve remission vs. control, and had the highest risk ratio of the 4 RCTs with positive outcomes.
Publication: Clinical Pharmacology & Therapeutics
Efficacy and tolerability of therapies set under pharmacogenetic tools suggestions: A systematic review with meta-analysis about mood disorders
This systematic review with meta-analysis aims to evaluate the utility of pharmacogenetic tests (PGT) in terms of efficacy and tolerability into the routine clinical treatment of mood disorders.
Publication: Psychiatry Res
The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis
Publication: J Affective Disorders
Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder
Recent clinical trials indicate that pharmacogenetic-guided treatment of major depressive disorder (MDD) results in higher treatment response rates by genetically matching patients to medications and avoiding a trial-and-error process.
Publication: J Manag Care Spec Pharm
Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings
Our study utilizes published health care costs and clinical patient outcome data to model the economic impact of pharmacogenetic-guided treatment for depression in a variety of clinical settings.
Publication: Neuropsychiatr Dis Treat
Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility
The objective of this study was to evaluate the effect of pharmacogenetics-guided treatment on patients diagnosed with depression and/or anxiety, in a diverse set of clinical settings, as compared to the standard of care.
Publication: J Psychiatr Res
Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix®) to Guide Treatment of Patients with Depression and/or Anxiety
IDgenetix, a novel pharmacogenomic test, has been shown to improve outcomes by predicting the likelihood of response to different psychotherapeutic medications.